Dewen Leng, Kai Cao, Qiang Hao, Zhu Peng, Gaofeng Pan, Jing Liu, Jie Yu, Junyi Tang, Jing Li, Han Chen, Huaiwen Chen, Hao Tang
{"title":"CD133-targeted afatinib nanomicelles for enhanced lung cancer theranostics.","authors":"Dewen Leng, Kai Cao, Qiang Hao, Zhu Peng, Gaofeng Pan, Jing Liu, Jie Yu, Junyi Tang, Jing Li, Han Chen, Huaiwen Chen, Hao Tang","doi":"10.1080/17435889.2024.2422804","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To develop a novel nanomicelle system to target and eradicate CD133-expressing lung cancer stem cells (CSCs) while imaging lung cancer.</p><p><strong>Methods: </strong>Averatinib nanomicelles with CD133 aptamers incorporated with gadolinium imaging reagents (M-Afa&Gd-CD133) were synthesized. The anticancer and imaging activities of M-Afa&Gd-CD133 were evaluated both in vitro and in vivo.</p><p><strong>Results: </strong>M-Afa&Gd-CD133 efficiently targeted CD133<sup>+</sup> lung CSCs and showed significant antitumor efficacy both in vitro and in vivo. Furthermore, M-Afa&Gd-CD33, as a T1 contrast agent, offers superior and sustained visualization of tumors over an extended period.</p><p><strong>Conclusion: </strong>M-Afa&Gd-CD133 represents a promising strategy for the theranostics of lung cancer.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-13"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2422804","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: To develop a novel nanomicelle system to target and eradicate CD133-expressing lung cancer stem cells (CSCs) while imaging lung cancer.
Methods: Averatinib nanomicelles with CD133 aptamers incorporated with gadolinium imaging reagents (M-Afa&Gd-CD133) were synthesized. The anticancer and imaging activities of M-Afa&Gd-CD133 were evaluated both in vitro and in vivo.
Results: M-Afa&Gd-CD133 efficiently targeted CD133+ lung CSCs and showed significant antitumor efficacy both in vitro and in vivo. Furthermore, M-Afa&Gd-CD33, as a T1 contrast agent, offers superior and sustained visualization of tumors over an extended period.
Conclusion: M-Afa&Gd-CD133 represents a promising strategy for the theranostics of lung cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
